BET1L: A Protein as A Drug Target for Various Diseases (G51272)

Target Name: BET1L

NCBI ID: G51272

BET1L

BET1L: A Protein as A Drug Target for Various Diseases

BET1L (GOLIM3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and is involved in a number of important cellular processes. In recent years, BET1L has been identified as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The protein BET1L is composed of 21 amino acid residues and has a calculated molecular weight of 18.9 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and is highly expressed in the brain, with lower levels found in the heart and kidneys. BET1L is involved in the regulation of cellular processes that are important for normal growth, development, and function.

One of the key functions of BET1L is its role as a regulator of cell growth and differentiation. BET1L plays a key role in the regulation of cell proliferation, by preventing the growth of cells that have too many copies of their DNA. This is important for the development and maintenance of tissues and organs, and for the regulation of tissues during development and repair.

In addition to its role in cell growth and differentiation, BET1L is also involved in the regulation of cell death. BET1L has been shown to play a role in the regulation of apoptosis, or programmed cell death, which is a natural and important process that helps remove damaged or dysfunctional cells from the body.

Another important function of BET1L is its role in the regulation of inflammation. BET1L has been shown to play a role in the regulation of immune responses, by preventing the activation and proliferation of immune cells that are involved in inflammation. This is important for maintaining a healthy immune system, and for preventing the development of autoimmune disorders.

In recent years, BET1L has been identified as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, BET1L has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. In addition, BET1L has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Despite the potential for BET1L as a drug target, much more research is needed to fully understand its role in these diseases. This is an area of active research, and the study of BET1L and its potential as a drug target is an important and promising area of study. Further research is needed to fully understand the role of BET1L in these diseases, and to develop effective treatments based on this understanding.

Protein Name: Bet1 Golgi Vesicular Membrane Trafficking Protein Like

Functions: Vesicle SNARE required for targeting and fusion of retrograde transport vesicles with the Golgi complex. Required for the integrity of the Golgi complex (By similarity)

The "BET1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BET1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets